

News Release

CLX Investment Company Announces eStrategy Solutions Agreement with Precherche, Inc. for Online Training and Testing

TEMECULA, Calif. – (Business Wire) – Nov. 3, 2005 – CLX Investment Company, Inc. (OTCBB:CLXN) today announced that portfolio investment company eStrategy Solution, an e-learning provider, has entered into an agreement to be the exclusive supplier of online testing and training for Precherche, Inc., a provider of clinical trial research services to the pharmaceutical, biotechnology, medical device, academic and pharmacovigilance industries.

eStrategy Solutions will be responsible for implementing online training content from material supplied by Precherche. Precherche is an application software company offering its trademarked clinical trial automation solution, **InterRx™**, that offers two distinctive advantages over available systems. It is the first solution to seamlessly automate the entire clinical trial process, and InterRx™ employs an agile architecture that allows for rapid implementation, flexibility to make changes quickly and tremendous ease-of-use.

Training content will be developed so that Precherche clients will have the ability to properly train their employees to input data that is gathered as a result of clinical trials into Precherche's online software solution. The Federal Drug Administration requires that anyone responsible for inputting data must receive specific training for each testing protocol.

Precherche stands alone in its ability to truly deliver the sought after "paperless" clinical trial, while adhering to all accepted clinical practices and regulatory requirements. For the first time, sponsors will be able to monitor the progress of their clinical trials in "near real time," enabling them to stop or correct trials of poorly performing drugs mid-trial, potentially saving tens of millions of dollars and avoiding costly delays. With the Precherche fixed price solution, sponsors will be able to better predict and manage their budgets. Precherche's objective is to enable sponsors to reduce by at least 30% the time and cost associated with conducting clinical trials.

"The Precherche opportunity came to eStrategy Solutions through our new chief information officer, Steve Matt, who has played an integral role in the early development of Precherche," commented John Matthews, president of eStrategy Solutions. "We strongly believe that Precherche will bring much-needed clinical trial automation solution services to the massive pharmaceutical, biotechnology, medical device, academic and pharmacovigilance markets.

"As the exclusive provider of online testing and training for Precherche, we expect that there will be a significant amount of work that we will be doing on behalf of this client," stated Mr. Matthews.

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings or other information is disclosed, please visit www.clxinvestments.com/email.asp

About the Company

CLX Investment Company (www.clxinvestments.com) has elected to be regulated as a Business Development Company pursuant to Section 54 of the Investment Company Act of 1940, and is pursuing a business plan wherein the Company seeks to make investment in developing companies with the goal of providing return for its shareholders.

CLX has acquired a 49% interest in eStrategy Solutions, Inc. (www.clxinvestments.com/estrategysolutions), a Texas-based e-learning provider that has developed online training solutions for government entities and other professional organizations. The Company has made an investment in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of “smart” scrolling advertising billboards. CLX holds a 20% equity interest in Zonda, Inc. (www.zondainc.com), a privately held company that specializes in test products that serve the medical diagnostic, bacterial food testing and environmental surfaces testing markets.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments’ control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Media Contacts

Art Adair

Innova Design & Advertising
artadair@hotmail.com
713-623-4432 ext. 109

Joi Chevalier

Precherche Life Sciences
jchevalier@precherche.com
512-233-0197